Brazil, Russia And India Offer The Best Opportunities In The Musculoskeletal Drugs Markets To 2020

Three of the BRICs (Brazil, Russia and India) have high recent and forecast market growth rates for musculoskeletal drugs and so will move up the table of consumer countries...

Three of the BRICs (Brazil, Russia and India) have high recent and forecast market growth rates for musculoskeletal drugs and so will move up the table of consumer countries for these drugs. Currently the largest markets for drugs that treat diseases such as arthritis, osteoporosis, osteomalacia, carpal tunnel syndrome and muscular dystrophy are in countries such as the USA and Japan and China; the USA’s market is and will remain vastly bigger than any other, but the three BRIC markets are beginning to catch up with Japan and China. For example, while India’s market was only two-thirds of Japan’s in 2016, by 2020 its sales will be equal to 84% of the Japanese sales. Again, Again, Brazil’s market was only half as big as China’s in 2016 but will be worth nearly 60% of that market by 2020.

Many musculosketal disorders are incurable so that patients will take these pain- and inflammation-reducing drugs either continuously or periodically for life. As their incidence is age-related, the increase in the size of the aging population is one factor driving the growth of this market. Other factors are increasing global obesity and stress levels.

Globally, the market for musculosketal drugs equates to about 14% of the pharma total and is growing at over 7% year on year. This compares with growth rates around 5% for pharmaceuticals in general.

The benefits of growth in these markets will be widely distributed. Although the leading manufacturers of these drugs are the Swiss company Hoffmann-La Roche, the British GlaxoSmithKline and the USA’s Pfizer, the top ten pharma companies together only account for around 10% of global sales. Small pharma companies in the emerging economies and generic drugs account for the majority of sales of these products.

Where to Learn More
Read Musculoskeletal Disorders Drugs Global Market Report 2018 from The Business Research Company for information on the following:

Markets Covered: Rheumatoid Arthritis, Muscle Relaxants, Others
Companies Mentioned: AbbVie, Amgen, Johnson & Johnson, F. Hoffmann-La Roche Ltd, and Pfizer Inc.
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Musculoskeletal Disorders Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293 Email: [email protected]

Categories
Business
No Comment

Leave a Reply

*

*